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Background: Significant toxicity in chemotherapy trials is usually defined as gradeX3. In clinical practice, however, multiple lower
grade toxicities are often considered meaningful. The purpose of this observational cohort study was to identify which level of
toxicity triggers treatment modification and early discontinuation of chemotherapy in older people.
Methods: Patients aged 65þ were recruited in a central London hospital. A total of 108 patients were recruited at the start of new
chemotherapy treatment between October 2010 and July 2012.
Results:Mean age was 72.1±5 years, median 72 and range 65–86 years. Of the patients, 50.9% (55) were male with gastrointestinal
(49), gynaecological (18), lung (15) and other cancers (26). Chemotherapy was palliative in 59.3% (64/108), curative/ neoadjuvant/
adjuvant in the others. Mean number of cycles completed was 4.2±3. Treatment modifications due to toxicity occurred in 60
(55.6%) patients, 35% (21/60) of whom had no greater than grade 2 toxicity. Early treatment discontinuation because of toxicity
occurred in 23 patients (21.3%), 39.1% (9/23) of whom had no greater than grade 2 toxicity.
Conclusions: Many older patients did not complete treatment as planned. Treatment was modified/discontinued even for one or
two low-grade toxicities. Further work is required to clarify whether low-grade toxicity has a greater clinical impact in older people,
or whether clinicians have a lower threshold for modifying/discontinuing treatment in older people.
Delivering chemotherapy to older people can be a challenge for
clinicians. Older people are living longer with a variety of
comorbidities of differing severities, functional deficits and degrees
of ‘frailty’. Consequently, decision-making in respect to chemo-
therapy can be complex. The decision includes evaluating who is
robust enough to tolerate chemotherapy, tolerate full dose
treatment and/or to continue through chemotherapy treatment
without modifications. A judgement needs to be made as to
whether the patient will actually gain benefit from the treatment. In
the absence of a unifying criteria beyond performance status (PS)
to assist decision-making, a subjective decision is made by the
individual clinician using the available information.
There are often concerns of increased risk of toxicity in older
people (Lichtman et al, 2007; Wedding et al, 2007). Some studies
indicate increased toxicity with age (Stein et al, 1995; Tsalic et al,
2003; Jantunen et al, 2006). However, these studies did not control
for comorbidities that may equally affect tolerance to chemo-
therapy. This raises the concern that comorbidity and not age is the
contributing risk factor (Wedding et al, 2007). The distinction is
essential as comorbidity is potentially modifiable (e.g., renal
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impairment, hypertension etc.) and sometimes reversible (e.g.,
incontinence). Conversely, several studies (clinical trials and real
life clinical practice analyses) have shown that older people have
equal benefit and tolerate treatment as well as younger people
(Giovanazzi-Bannon et al, 1994; Sargent et al, 2001; Garcia-Suarez
et al, 2003; Goldberg et al, 2006; Mitry and Rougier, 2009; Park
et al, 2012). A pooled reanalysis of large clinical trials has shown
that older patients received the same benefit as younger patients
without an increase in toxicity (Giovanazzi-Bannon et al, 1994.
However, these pooled analyses did not report the selection criteria
for the clinical trials, nor important characteristics (e.g., comorbid-
ities) which would enable a judgement to be made regarding the
relevance of these results to clinical practice. Older people included
in clinical trials are likely to have a better PS and fewer
comorbidities than the whole population of older people with
cancer, and thus are not representative of the heterogeneous group
seen in clinical practice, about which there is little published
literature.
The paucity of clinical information makes it harder to make
evidence-based decisions around the management of chemo-
therapy in older people (Lichtman et al, 2007; Wu and Goldberg,
2013). Older people are underrepresented in clinical trials (Yee
et al, 2003). There are a number of factors contributing to this
including the exclusion of older people from clinical trials, either
because of study protocols excluding comorbidities common in
older people or by upper age limits (Droz et al, 2008). In addition,
even where eligible, oncologists have been observed to be less likely
to include older people in trials (Benson et al, 1991). The risk/
benefit decision is consequently often influenced by either
observational study evidence, subgroup analyses and/or by the
previous experience of the individual clinician (Wu and Goldberg,
2013). There may be less clinical confidence in assessing this risk in
older people – this has been observed by oncologists in training
(Kalsi et al, 2013).
In addition, the analysis and reporting of toxicity within clinical
trials is more focussed on severe toxicity usually defined as
National Cancer Institute Common Toxicity Criteria (NCI-
CTCAE version 4.0) grade 3–4. In clinical practice, the occurrence
of multiple lower grade toxicities is often considered clinically
relevant and may result in changes in clinical decision-making. We
hypothesise that multiple low-grade toxicities may be a common
reason for treatment modification/discontinuation in older people.
The purpose of this observational cohort study was to:
1. Identify which grade(s) of toxicity (and how many) trigger
(i) treatment modification (defined as dose reductions, delays
or drug omissions) and (ii) early discontinuation of treatment.
2. Identify the factors associated with modifications/discontinuation
made because of low-grade toxicity.
MATERIALS AND METHODS
Study design and setting. This prospective observational cohort
study was set in a London teaching hospital between February 2010
and October 2012. A total of 516 patients aged 65þ undergoing
treatment for cancer (chemotherapy, radiotherapy, surgery, watch-
ful waiting) were recruited to the overall study with the aim of
identifying comorbidity and comprehensive geriatric assessment
(CGA) characteristics that are associated with poorer treatment
tolerance (Ethics approval: LREC 09H71865). The primary
outcomes of interest for the overall study included toxicities,
surgical complications, treatment modifications/non-completion
and disease control/progression. This study examines a subgroup
of 108 patients who were recruited at the start of new
chemotherapy treatment (recruited between October 2010 and
July 2012). Patients excluded from this analysis either received a
non-chemotherapy treatment modality or were not recruited at the
start of chemotherapy. All participants provided consent and
were asked to complete a baseline questionnaire (CGA-GOLD)
(available in the online Supplementary Material). This included
self-reported comorbidities and all CGA domains (e.g., falls,
incontinence, delirium, psychosocial, instrumental and basic
activities of daily living) (Balducci, 2003; Chen et al, 2003;
Minisini et al, 2004; Terret et al, 2004; Extermann et al, 2005;
Gosney, 2005; Hurria et al, 2005, 2007; Mohile et al, 2007; Rodin
and Mohile, 2007; Girre et al, 2008), quality of life (EORTC QLQ-
C30) (Aaronson et al, 1993) and additional questions from our
user consultation.
Self-reported CGA has been feasibly conducted in cancer
outpatients in the US and Europe (Ingram et al, 2002; Hurria et al,
2005; Girre et al, 2008; Marenco et al, 2008). The feasibility and
utility as well as validity and reliability of CGA-GOLD has been
previously reported (Kalsi et al, 2013, 2014). Oncologists were
blinded to the questionnaire responses and so consented patients
received unbiased care according to standard clinical management.
Subjects. Potential participants were identified from oncology
clinic lists and chemotherapy day unit lists on the hospital
electronic record system. Patients were mailed study information
and given a minimum of 48 h to consider participation prior to
consent. Questionnaires were returned by participants by post.
Patients aged 65þ with cancer recruited prior or within the
first cycle of chemotherapy were included in the analysis. Patients
receiving concomitant radiotherapy were also included. Patients
receiving both neoadjuvant and adjuvant chemotherapy only had
one of these schedules assessed for toxicity (whichever was closest
to the recruitment date). The rationale was to avoid contamination
of the chemotherapy toxicity outcome by post-operative side
effects.
Data collection. Data were collected using the hospital electronic
patient records. Patient characteristics (age, comorbidities, PS)
were identified from patient records. Clinical outcomes were
followed up for 6 months from the first dose of chemotherapy.
Toxicity data and treatment changes were identified by review of
prospectively recorded oncology electronic notes and clinical
letters. Reasons for treatment changes (i.e., if toxicity related)
were also identified in the same way. Patients were followed up for
toxicity data to the end of the treatment course, or if chemotherapy
was given for longer than 6 months, toxicity follow-up ceased at
6 months to avoid skewing of data as a validated approach
(Extermann et al, 2011). Toxicity during the treatment course was
recorded as per the grades documented in the clinical notes entry.
Where clinicians had not graded toxicity but had adequately
described the toxicity, grading was assigned retrospectively using
NCI-CTCAE version 4.0. Laboratory results during chemotherapy
were reviewed to identify haematological toxicity and graded using
NCI-CTCAE version 4.0.
Patients who were identified as having treatment modified or
discontinued because of toxicity were then further examined to
identify the grades of toxicities during their treatment course.
Those with modifications/discontinuation who only suffered low-
grade toxicity were further examined for the number of low-grade
toxicities occurring in their treatment course.
Statistical analysis. Toxicity data were dichotomised to low-grade
(grade 1–2) and high-grade (grade 3þ ) toxicity. Participants were
described as suffering low or high toxicity based on the highest
recorded grade of toxicity for the individual. Predictors were also
prospectively dichotomised (age: o75 vs 75þ , comorbidities: o4
vs 4þ , PS: 0–1 vs 2–3 and treatment intent: curative/adjuvant/
neoadjuvant vs palliative). Associations between predictors and
treatment modification and discontinuation because of low-grade
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toxicity were investigated with univariate analysis using w2 or
Fisher’s exact test if the expected frequency was less than 5. SPSS
version 19 statistical software package (SPSS, Inc., Chicago, IL,
USA) was used for data analysis.
RESULTS
Fifty-three participants were recruited prior to the first cycle and
55 within the first cycle of chemotherapy. All 108 completed
follow-up as planned. Ninety-one completed the 6-month follow-
up, 17 (15.7%) to the point prior to 6 months at which they died
(Figure 1).
The mean age of participants was 72.1±5 years, median 72,
range 65–86. Of them, 50.9% (n¼ 55) were male and 89.5%
(n¼ 94) white; 82.5% were PS 0–1, 14.6% PS 2 and 2.9% PS 3.
Participants had gastrointestinal (49), gynaecological (18), lung
(15) and other cancers (26). More than three active comorbidities
were present in 50% of the cohort. The most common
comorbidities were hypertension (39.6%), cardiac disease
(23.6%), musculoskeletal disease (22.6%), hypercholesteraemia
(21.7%), respiratory disease (17.0%), thrombo-embolism (17.9%)
and diabetes (14.2%).
Chemotherapy was palliative in 59.3% (64/108) and curative/
adjuvant/neoadjuvant in 40.7% (44/108). Forty-seven different che-
motherapy regimens were administered, 16.7% with concomitant
radiotherapy; 76.9% (83) had full dose at the outset. Median
chemotherapy cycles completed were 4, mean 4.2±3, range 1–12.
Table 1 describes toxicity incidence and Table 2 describes the
incidence of the most common individual toxicities by grade.
Toxicity (all grades) occurred in 93.5% of participants, 50.9% with
grade 3þ and 42.6% with low grade. The most common low-grade
toxicities included fatigue, nausea, diarrhoea, constipation and
haematological toxicity. The number of missing toxicity data was
small (0.46%).
Treatment changes due to toxicity. Treatment modification due
to toxicity occurred in 60 patients, 35% (21/60) of whom had no
greater than grade 2 toxicity. Of these 21, the mean number of low-
grade toxicities resulting in treatment modification was 2.19±1.33,
7 patients had only one grade 2 toxicity. Most common low-grade
toxicity types resulting in treatment modification were fatigue (8),
haematological (8), gastrointestinal (6) and infections (5).
Non-completion of treatment because of toxicity occurred in 23
patients, 39.1% (9/23) of whom had no greater than grade 2
toxicity. Of these nine, the mean number of low-grade toxicities
resulting in treatment discontinuation was 1.78±1.20, three had
only one grade 2 toxicity, one patient only grade 1 toxicity. Most
common low-grade toxicities resulting in treatment discontinua-
tion were fatigue (5) and haematological toxicity (4). A further 24
patients did not complete treatment because of disease progression.
Factors associated with toxicity-related treatment modifications/
discontinuation. Table 3 demonstrates univariate associations of
age, comorbidity, PS and treatment intent with low-grade toxicity
(vs high) resulting in treatment modifications and discontinuation.
Low-grade toxicity triggering treatment modification was asso-
ciated with a higher comorbid burden (4þ comorbidities),
P¼ 0.01. There was no association between low-grade toxicity
and age, PS or treatment intent triggering treatment modification
or discontinuation.
DISCUSSION
Low-grade toxicity appears to have clinical significance in older
people undergoing chemotherapy. Many older patients did not
complete treatment as planned. Low-grade toxicity resulted in
treatment modification for 19.4% (21/108) and treatment dis-
continuation for 8.3% (9/108) of the whole cohort. Treatment was
modified/discontinued even for one or two low-grade toxicities.
The accumulation of these low-grade toxicities appear important in
determining future dosing and ongoing treatment. Fatigue and
haematological toxicity were the most common low-grade
toxicities impacting on treatment change.
Modifications due to low-grade toxicity was not associated with
age. A number of older people were able to complete a reasonable
amount of chemotherapy (median 4 cycles). Treatment modifica-
tion for low-grade toxicity occurred more often in those with
multiple comorbidities. This study would thus support that
treatment decision-making should not be driven by chronological
age and that comorbid burden appears far more relevant.
To the authors’ knowledge, this is the first study specifically
investigating the impact of low-grade toxicity in older people
undergoing chemotherapy. Other studies in older people have been
performed investigating the impact of toxicity in general on
chemotherapy completion. In a study of 171 patients with small
Overall study participants : 516
Met inclusion criteria: 108 Excluded from subgroup
analysis: 408
Completed 6 month
follow-up: 91
Completed follow-up to death (occurring
prior to 6 month follow-up): 17
Figure 1. Results – participants.
Table 1. Incidence of toxicity
All grades % (N) Grade 1–2 % (N) Grade 3þ % (N)
Non haematological toxicities 92.6 (100/108) 60.2 (65/108) 32.4 (35/108)
Haematological toxicity 66.7 (72/108) 37.0 (40/108) 29.6 (32/108)
Treatment modification due to toxicity 55.6 (60/108) 19.4 (21/108) 36.1 (39/108)
Treatment discontinued due to toxicity 21.3 (23/108) 8.3 (9/108) 13.0 (14/108)
Table 2. Incidence of most common toxicities by grade
Toxicity Grade 1–2 % (N) Grade 3þ % (N)
Fatigue 50.9 (55/108) 10.2 (11/108)
Nausea 37.0 (40/108) 2.8 (3/108)
Lymphocytopenia 35.2 (38/108) 11.1 (12/108)
Diarrhoea 34.2 (37/108) 4.6 (5/108)
Thrombocytopenia 25.0 (27/108) 3.7 (4/108)
Constipation 25.0 (27/108) 0 (0/108)
Peripheral neuropathy 23.1 (25/108) 3.7 (4/108)
Anaemia 19.4 (21/108) 11.1 (12/108)
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cell lung cancer, 117 of whom who received chemotherapy, 40
patients had a dose reduction and 56 patients did not complete
treatment as planned (Fisher et al, 2012). Toxicity (grades not
specified) was the most common reason for treatment change. Of
those with dose reductions, 75% were due to haematological
toxicity and 25% due to frailty/PS. Of those with early
discontinuation, 56% were discontinued because of haematological
toxicity, 34% non-haematological toxicity, 44% related to frailty/PS
and 25% medical reasons. Another study of 108 elderly patients
with a variety of cancer types also identified haematological
toxicity to be associated with relative dose intensity in regression
analyses (Luciani et al, 2006). A study of 532 patients (all ages)
with a variety of tumour groups also looked at the impact of
adverse drug reactions on chemotherapy completion (Llopis-Salvia
et al, 2010). Of the 3553 chemotherapy cycles, 12.9% were not
delivered as planned because of adverse drug reactions. Adverse
drugs reactions caused treatment delays X7 days for 307 cases,
dose reductions for 91, dose omissions in 29 and treatment
discontinuation in 112 cases.
This study investigates a very large but understudied
population. We examined impact according to age, PS,
comorbidity and treatment intent. A variety of tumour
and chemotherapy types have been included in the analysis
improving generalisability.
This study has limitations. The cohort is small and our sub-
optimal sample size may contribute to some non-significant
results. We did not study patients under the age of 65. We cannot
exclude that a similar study conducted in younger patients may
reveal similar findings. A high proportion of participants had PS 0–1.
Future work could compare younger matched controls and/or
specifically target older people with PS 2þ . Toxicity was also
identified from that documented in routine clinical practice
because of the limitations in size of the research team. This may
risk underreporting of toxicity when compared with a clinical trial
setting. These results need internal and external validation in a
larger sample size to allow for appropriate multivariate analysis to
more thoroughly investigate for associations.
This study has potentially significant implications. It highlights
that the measure and reporting of lower grade toxicity and its
impact should be considered in the design of future clinical trials,
especially low-grade fatigue and haematological toxicity. This
would better reflect real life clinical decision-making and would
assist clinicians in making evidence-based decisions regarding the
risks of a particular chemotherapy.
Key questions are also raised. Does low-grade toxicity truly have a
greater clinical impact on older people? Or is there a lower threshold
for modifying/discontinuing treatment in older people? If so, why?
Or is treatment modified for low-grade toxicity similarly in younger
people? And finally, as highlighted by the 2012 Department of
Health report ‘Cancer Services coming of Age’ (Department of
Health, 2012), it may be beneficial to medically ‘optimise’ older
people for chemotherapy. Comorbidities and functional deficits
should be thoroughly assessed and modified where possible prior to
starting chemotherapy. Strategies should be sought aimed at
ameliorating/optimising significant grade 2 toxicities such as fatigue
and haematological toxicity (e.g., increasing the use of growth factor
support, pre-treatment optimisation of anaemia).
Cancer services should consider reconfiguration of the multi-
disciplinary team to include geriatricians to support the wider
needs of older people. Medical and social optimisation may
improve the impact of low-grade toxicity on the ability of patients
to receive and complete chemotherapy as planned.
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